MX2019015402A - Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso. - Google Patents

Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.

Info

Publication number
MX2019015402A
MX2019015402A MX2019015402A MX2019015402A MX2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A MX 2019015402 A MX2019015402 A MX 2019015402A
Authority
MX
Mexico
Prior art keywords
diseases
polypeptides
mtsp
inhibit
methods
Prior art date
Application number
MX2019015402A
Other languages
English (en)
Spanish (es)
Inventor
Edwin L Madison
Vanessa Soros
Mikhail Popkov
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of MX2019015402A publication Critical patent/MX2019015402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Photolithography (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicinal Preparation (AREA)
MX2019015402A 2017-06-22 2018-06-21 Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso. MX2019015402A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523735P 2017-06-22 2017-06-22
US201862664051P 2018-04-27 2018-04-27
PCT/US2018/038844 WO2018237201A1 (en) 2017-06-22 2018-06-21 MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE

Publications (1)

Publication Number Publication Date
MX2019015402A true MX2019015402A (es) 2020-07-20

Family

ID=63015005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015402A MX2019015402A (es) 2017-06-22 2018-06-21 Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.

Country Status (19)

Country Link
US (5) US10781435B2 (cg-RX-API-DMAC7.html)
EP (1) EP3641801A1 (cg-RX-API-DMAC7.html)
JP (3) JP7091373B2 (cg-RX-API-DMAC7.html)
KR (1) KR102675270B1 (cg-RX-API-DMAC7.html)
CN (1) CN111107870A (cg-RX-API-DMAC7.html)
AU (2) AU2018290281B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019027583A2 (cg-RX-API-DMAC7.html)
CA (2) CA3067851C (cg-RX-API-DMAC7.html)
CL (3) CL2019003813A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020000584A2 (cg-RX-API-DMAC7.html)
IL (2) IL271587B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20190288A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019015402A (cg-RX-API-DMAC7.html)
MY (1) MY202652A (cg-RX-API-DMAC7.html)
PE (1) PE20200697A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502838A1 (cg-RX-API-DMAC7.html)
SG (3) SG10202110500TA (cg-RX-API-DMAC7.html)
WO (1) WO2018237201A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202000332B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
PE20200697A1 (es) * 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
JP7462560B2 (ja) 2018-01-03 2024-04-05 パレオン ファーマシューティカルズ インコーポレイテッド 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
MX2022000032A (es) * 2019-07-03 2022-06-15 Palleon Pharmaceuticals Inc Sialidasas recombinantes y métodos de utilización de las mismas.
US11396529B2 (en) * 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same
KR20230142496A (ko) * 2021-01-08 2023-10-11 버텍스 파마슈티칼스 인코포레이티드 인자 b 프로테아제
CN113456527B (zh) * 2021-07-30 2023-04-07 北京清大赛尔生物科技有限公司 一种nadh微胶囊制剂及其制备方法和应用
WO2024205149A1 (ko) * 2023-03-24 2024-10-03 카오티에스 주식회사 신규한 그랜자임 융합단백질 및 이의 용도
CN119570766B (zh) * 2025-02-08 2025-05-16 上海锴泰生物科技有限公司 一种胶原蛋白酶突变体、基因片段、重组质粒、重组表达体系、胶原蛋白肽,及其制备方法和用途
CN121538228B (zh) * 2026-01-21 2026-04-10 山东寿光巨能金玉米开发有限公司 一种NCgl0081基因突变体及其在制备L-赖氨酸中的应用

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795A (en) 1848-09-19 Saddletree for carts
US237A (en) 1837-06-15 Egbert beale
US5990A (en) 1848-12-26 of baltimore
US569A (en) 1838-01-09 Caruiag-e-spiiln g
US844A (en) 1838-07-17 Boiler for
US5324A (en) 1847-10-09 Cooking-stove
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
EE9600121A (et) 1994-03-31 1997-04-15 Amgen Inc. Megakarüotsüütide kasvu ja diferentseerumist stimuleerivad kompositsioonid ja meetodid
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
WO2000002017A2 (en) 1998-07-03 2000-01-13 Neles Field Controls Oy Method and arrangement for measuring fluid
US6153394A (en) 1998-09-18 2000-11-28 Board Of Trustees Operating Michigan State University Immunoassay for equine protozoal myeloencephalitis in horses
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU7497000A (en) 1999-02-28 2000-11-14 Washington University Novel transduction molecules and methods for using same
EP1161266A4 (en) 1999-03-12 2007-09-19 Univ Georgetown Matriptase, a serine protease and its applications
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2005506047A (ja) 2001-03-27 2005-03-03 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー 膜貫通型セリンプロテアーゼ9をコード化する核酸分子、コード化されたポリペプチドおよびそれらに基づく方法
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1436315A2 (en) 2001-10-19 2004-07-14 The Scripps Research Institute Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7192468B2 (en) 2002-04-15 2007-03-20 Fluor Technologies Corporation Configurations and method for improved gas removal
WO2003104394A2 (en) 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US20060024289A1 (en) 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
WO2004031733A2 (en) 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
EP2474630B1 (en) 2002-12-20 2016-04-27 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US20060178297A1 (en) 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
US20060222657A1 (en) 2003-06-20 2006-10-05 Dowdy Steven F Polypeptide transduction and fusogenic peptides
US7439226B2 (en) 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005110453A2 (en) * 2004-04-12 2005-11-24 Catalyst Biosciences, Inc. Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US8173144B2 (en) 2004-11-04 2012-05-08 L'oreal Administration of urea compounds for combating signs of cutaneous aging
EP1851543A2 (en) 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
AU2011218753B2 (en) * 2005-10-21 2013-10-24 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
KR101126423B1 (ko) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
AU2006308989A1 (en) 2005-11-01 2007-05-10 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Novel protein transduction domains and uses therefor
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP5295785B2 (ja) 2006-02-20 2013-09-18 エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション 細胞膜透過性ペプチド
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
ES2372709T3 (es) 2006-07-05 2012-01-25 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
CA2791144C (en) * 2006-07-05 2019-04-09 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
CA2843631A1 (en) 2011-10-14 2013-04-18 Alain Moreau Methods and kits for diagnosing and/or prognosing osteoarthritis
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10029415B2 (en) 2012-08-16 2018-07-24 Stratasys, Inc. Print head nozzle for use with additive manufacturing system
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
CA2836167A1 (en) 2013-12-10 2015-06-10 Christina Xiaolin Dai Thickness increase spring
SG11201608358VA (en) * 2014-04-29 2016-11-29 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
PE20200697A1 (es) 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法

Also Published As

Publication number Publication date
JP2020528742A (ja) 2020-10-01
BR112019027583A2 (pt) 2020-10-06
PH12019502838A1 (en) 2020-09-21
JOP20190288A1 (ar) 2019-12-16
CL2021003080A1 (es) 2022-08-12
NZ760116A (en) 2024-03-22
KR102675270B1 (ko) 2024-06-17
AU2018290281B2 (en) 2021-12-16
CA3067851A1 (en) 2018-12-27
PE20200697A1 (es) 2020-06-16
CL2019003813A1 (es) 2020-05-29
IL271587B1 (en) 2024-01-01
IL271587B2 (en) 2024-05-01
SG10202110492YA (en) 2021-11-29
IL308949B1 (en) 2025-11-01
IL308949A (en) 2024-01-01
US11401513B2 (en) 2022-08-02
CL2021003081A1 (es) 2022-08-12
US20190093097A1 (en) 2019-03-28
US12173337B2 (en) 2024-12-24
AU2022201445A1 (en) 2022-03-24
US20210355474A1 (en) 2021-11-18
JP7773579B2 (ja) 2025-11-19
JP2024095662A (ja) 2024-07-10
US20240018502A1 (en) 2024-01-18
KR20200030063A (ko) 2020-03-19
CA3067851C (en) 2023-01-31
SG10202110500TA (en) 2021-11-29
US11807882B2 (en) 2023-11-07
IL271587A (en) 2020-02-27
US20200291376A1 (en) 2020-09-17
JP7091373B2 (ja) 2022-06-27
JP2022120155A (ja) 2022-08-17
SG11201912071QA (en) 2020-01-30
US10781435B2 (en) 2020-09-22
US10954501B2 (en) 2021-03-23
US20210032617A1 (en) 2021-02-04
CN111107870A (zh) 2020-05-05
CO2020000584A2 (es) 2020-05-05
ZA202000332B (en) 2024-12-18
CA3177086A1 (en) 2018-12-27
WO2018237201A1 (en) 2018-12-27
MY202652A (en) 2024-05-13
EP3641801A1 (en) 2020-04-29
AU2022201445B2 (en) 2023-11-23
IL308949B2 (en) 2026-03-01
AU2018290281A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CL2021003080A1 (es) Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)
CO2021008338A2 (es) Polipéptidos de activador de plasminógeno, tipo urocinasa, modificados y métodos de uso
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MX2023000731A (es) Composiciones utiles para enzimas de internalizacion.
DOP2018000151A (es) Composiciones y métodos para disminuir la expresión de tau
WO2018069500A3 (en) Anti-lag-3 antibodies and compositions
CO2018003465A2 (es) Métodos y composiciones para tratar afecciones asociadas con respuestas inflamatorias anormales
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MA40132A1 (fr) Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
MX372988B (es) Composiciones oftalmicas estabilizadas de omega 3.
CO2017000056A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
MX2018010395A (es) Formulaciones topicas que contienen cliclosporina y usos de las mismas.
MX2019002288A (es) Suspensión celular para usarse en el tratamiento de la arteriopatía periférica de las extremidades inferiores.
EA201891919A1 (ru) Способы трансфекции растений и сокращения событий случайной интеграции
MX2016015635A (es) Metodos y composiciones para evitar la lesion por isquemia-reperfusion en organos.
EA202091325A1 (ru) Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток
CO2018003596A2 (es) Arnip y su uso en métodos y composiciones para la inhibición de la expresión del gen nrarp
GB2530224A (en) Enhancement of osteogenic potential of bone grafts
EA202000017A1 (ru) Модифицированные пептиды сериновой протеазы 1 мембранного типа (mtsp-1) и способы применения
EA201991371A1 (ru) Лечение лимфедемы и связанных состояний с использованием плацентарных адгезивных клеток
EP3645706A4 (en) AUTOLOGOUS STEM CELL THERAPIES FOR THE TREATMENT OF EYE DISEASE